This week, the Computer and Personal Electronics, Energy Services, Computer and Personal Electronics, Oil and Gas, and Marine sectors look weak according to Portfolio Grader.
With 78% of its stocks (74 out of 95) rated “sell,” the Metals and Mining sector is struggling this week. Out of the Metals and Mining stocks, Cliffs Natural Resources (NYSE:), Walter Energy (NYSE:), and Thompson Creek Metals Company Inc. (NYSE:) are near the bottom with F’s. Over the last 12 months, Walter Energy is the worst performer in this sector, with a 74.6% decline.
Best Airline Companies To Invest In Right Now: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion:- [By Johanna Bennett]
Two months since becoming chief executive at Forest Laboratories (FRX), and Brenton Saunders is putting his mark on the drug maker.
On Monday, Forest outlined ��roject Rejuvenate,��a plan to cut costs $500 million by 2016, while scaling back research and development efforts and reducing the company�� work force.
It�� been a common story among big pharmaceutical companies. The industry has grown to depend on acquisitions and licensing deals or partnerships with small drug makers rather than in-house efforts to produce the blockbuster products needed to grow sales and offset revenue lost to generic rivals.
Investors seem to approve. At $55.54, the stock surged 8.2% during afternoon market action.
It was actually a pretty busy day for Forest. Though it restructuring plans attracted the most attention, the company also announced the sale of $1 billion of new debt to help fund $400 million in accelerated stock buybacks as part of a larger $1 billion share repurchase plan and a $250 million deal to acquire exclusive rights to the schizophrenia medication Saphris from Merck & Co. (MRK).
Altogether, it could be quite a boon for Forest�� bottom line. Leerink Swann analyst Seamus Fernandez raised his per share earnings estimate for 2015 and 2016 to $2.89 and $3.24 respectively from the previous $1.87 and $1.19. Fernandez writes:
We see several potential accretive Saphris-like opportunities for FRX particularly as companies like MRK partner or exit cost-intensive primary care/specialty categories (e.g., respiratory, antibiotics/antifungal, cardiology, GI, CNS). Incorporating these changes (and assuming no impact to sales ests of FRX’s existing portfolio), our new DCF valuation increases to $63/shr.
5 Best Building Product Stocks To Invest In Right Now: Forestar Group Inc (FOR)
Forestar Group Inc. (Forestar) is a real estate and natural resources company. The Company owns directly or through ventures almost 147,000 acres of real estate located in nine states and 12 markets and about 595,000 net acres of mineral interests. As of December 31, 2011, the Company had approximately 131,000 acres of timber on its 147,000 real estate acres and about 17,000 acres of timber under lease. During the year ended December 31, 2011, the Company generated revenues of $136 million. It operates in three segments: Real estate, Mineral resources and Fiber resources. Its real estate segment generated 78% of its 2011 consolidated revenues. The Company sells wood fiber from portions of its land, primarily in Georgia, and lease land for recreational uses. It leases its mineral interests to third parties for the exploration and production of oil and natural gas, principally in Texas and Louisiana. On January 20, 2012, it sold its 25% interest in Palisades West LLC to Dimensional Fund Advisors L.P. In September 2012, the Company acquired CREDO Petroleum Corp.
Real estate
In the Company�� real estate segment, it conducts an array of project planning and management activities related to the acquisition, entitlement, development and sale of real estate, primarily residential and mixed-use communities. It owns and manages its projects either directly or through ventures. Its development projects are principally located in the markets of Texas. The Company has over 16,000 acres entitled, developed and under development, consisted of land planned for over 27,000 residential lots and about 2,500 commercial acres. In 2011, it sold over 17,000 acres of undeveloped land through its retail land sales program. In addition, it sold 112 entitled acres from two residential projects. The majority of its projects are single-family residential and mixed-use communities. During 2011, the Company acquired 180 substantially completed residential lots in Houston, Texas; three multifamily develo! pment sites located in Austin, Denver, and Dallas.
The Company develops lots for single-family homes and develops multifamily properties on its commercial tracts or other developed sites it may purchase. In addition, the Company sells commercial tracts that are ready for construction of buildings for retail, office, industrial or other commercial uses. It sells residential lots primarily to national and regional homebuilders and, to a lesser extent, local homebuilders. The Company has 75 entitled, developed or under development projects in seven states and 11 markets, principally in the markets of Texas, encompassing over 16,000 remaining acres, consisted of land planned for over 27,000 residential lots and about 2,500 commercial acres. It also markets and sells undeveloped land through its retail sales program.
Commercial tracts are developed internally or sold to or ventured with commercial developers that specialize in the construction and operation of income producing properties, such as apartments, retail centers, or office buildings. The Company also sells land designated for commercial use to regional and local commercial developers. It has about 2,500 acres of entitled land designated for commercial use. Cibolo Canyons is a mixed-use project in the San Antonio market area.
Mineral Resources
The Company owns mineral interests beneath approximately 595,000 net acres located in the United States, principally in Texas, Louisiana, Georgia and Alabama. It is engaged in leasing certain portions of these mineral interests to third parties for the exploration and production of oil and natural gas. Of the Company�� 595,000 net acres of mineral interests, about 515,000 net acres are available for lease. It has about 80,000 net acres leased for oil and natural gas exploration activities, of which about 32,000 net acres are held by production from over 530 oil and natural gas wells that are operated by others. During 2011, the Company acquired unproved le! asehold p! roperties associated with 13,000 net mineral acres in Alabama and Georgia.
The Company has about 251,000 net mineral acres in East Texas and about 144,000 net mineral acres in Louisiana located within the East Texas and Gulf Coast Basins. It has mineral interests in and around production trends in the Wilcox, Frio, Cockfield, James Lime, Pettet, Travis Peak, Cotton Valley, Austin Chalk, Haynesville Shale and Bossier formations. The Company has about 1,000 net mineral acres in the Fort Worth Basin. It also has mineral interests in and around the Barnett Shale. The Company has about 40,000 net mineral acres in Alabama and about 157,000 net mineral acres in Georgia. The Company did not drill any wells in 2011.
Fiber Resources
The Company has about 131,000 acres of timber it owns directly or through ventures and about 17,000 acres of timber under lease. In 2011, it sold to Temple-Inland, over 323,000 tons of timber from its lands. During 2011, about 131,000 acres of its land, primarily in Georgia, were leased for recreational purposes. During 2011, the Company sold 57,000 acres of timberland in Georgia, Alabama, and Texas.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Forestar Group (NYSE: FOR ) , whose recent revenue and earnings are plotted below. - [By Andy Batts]
The shares of Forestar Group (FOR) are trading at ~30% discount to the company's NAV. The company operates in three business segments: real estate, oil and gas, and other natural resources. Forestar has a rich portfolio of assets and businesses, including 133,000 acres of real estate; 752,000 acres of oil and gas properties; 1.5 million acres of water rights; and 275,000 acres of timberland.
5 Best Building Product Stocks To Invest In Right Now: Edp Energias de Portugal SA (EDPFY.PK)
EDP Energias de Portugal SA (EDP), incorporated in 1976, is a Portugal-based company engaged in the electric energy and gas sectors. The Company develops its activities in the business areas of generation, supply and distribution of electricity and supply and distribution of gas. The Company operates through six business units: Electricity Generation, Renewable Energies, Electricity Distribution, Electricity Supply, Gas and Brazil Operations. EDP is also present in electricity generation, supply and distribution in Brazil, Spain and the United States. In April 2008, the Company acquired EDP Renovaveis through Nuevas Energias de Occidente (NEO). In February 2008, Horizon Wind Energy, LLC, EDP�� 100%-owned subsidiary for United States wind operations, acquired from Hydra Energy, LLC, a portfolio of six early stage projects in an aggregate of 1,050 megawatts of wind capacity, located in the States of Illinois, Indiana and Ohio, the United States.
Electricity Generation
In Spain, EDP operates through HC Energia. Cogeneration consists of simultaneous production of power and steam using thermal technology, such as in the form of natural gas turbines. Cogenerators are usually attached to an industrial customer or services, to which they supply the electricity and steam they need. Energy generation includes a centralised energy management platform responsible for actively managing the price and volume risks for the EDP Company�� portfolio in the Iberian Peninsula.
Renewable Energies
The Company�� electricity from renewable energies is generated by its subsidiary NEO, and in the United States of America by its subsidiary Horizon Wind Energy. In July 2007, EDP acquired 100% interest in Horizon, a developer, owner and operator of wind power generation in the United States, from the Goldman Sachs Group, Inc. In September 2007, Horizon owned 941 gross megawatt of operating wind projects and has 615 megawatt of projects under construction, for expected operational ! capacity of 1.556 gross megawatts (1.324 net megawatts).
Electricity Distribution
EDP develops the regulated electricity distribution activity in mainland Portugal and in Spain in the Asturias region and to a lower extent in Madrid, Valencia and Alicante. Electricity distribution activity is a regulated activity that consists in bringing the electricity, through the distribution network, from the transport network substations to the final consumption points. Within the scope of this activity, EDP builds, operates and maintains the distribution network and other installments aimed at electricity distribution, granting service quality and direct and customized assistance.
EDP Distribuicao Energia, S.A. is EDP�� company operating in the regulated distribution and supply businesses in Portugal. EDP�� distribution activity is regulated by energy service regulator (ERSE), which defines the tariffs, parameters and prices for electricity and other services in Portugal, controlling and assuring the levels of quality and service demanded by the Direccao Geral de Geologia e Energia (DGGE). EDP Distribuicao is holder of an open-ended binding license for the business of distribution of medium- and high-voltage electricity in mainland Portugal. It is also the concessionaire for almost all the low-voltage distribution network, in accordance with concession contracts with the municipalities. HC Energia operates in the regulated electricity distribution and supply business, with its natural market being the region of Asturias. HC Energia�� network covers the Asturias, Valencia, Madrid and Alicante regions.
Electricity Supply
EDP's electricity supply offers the services, such as maintenance and assistance services, services aimed at electricity quality, specialized technical services and energy efficiency services. EDP operates in Portugal through EDP Comercial, while in Spain, its electricity supply service is obtained from HC Energia or Naturgas, ! which off! ers its customers an integrated portfolio of gas and electricity products.
Gas
EDP has a presence in the gas sector in the Iberian Peninsula, through Naturgas in Spain, and through EDP Gas in Portugal. Naturgas market is the Basque Country, and Asturias, and it operates in the Spanish gas sector by providing services, such as transport, distribution and supply of gas; supply of gas in the liberalized market, and sourcing and trading.
Brazil Operations
EDP is present in Brazil through Energias do Brasil, a 62.4%-owned subsidiary. Energias do Brasil operates in the electricity generation, distribution and supply businesses.
Advisors' Opinion:- [By David Hunkar]
Current Dividend Yield: 6.43%
Company: Edp Energias De Portugal SA (EDPFY.PK)
Sector: Telecom
Country: AustraliaCurrent Dividend Yield: 4.68%
Sector: Electric Utilities
Country: Portugal
5 Best Building Product Stocks To Invest In Right Now: Ciber Inc (CBR)
CIBER, Inc. (CIBER) is a provider of information technology (IT), business consulting and outsourcing services. The Company is engaged in solving complex IT and business issues across industries, such as energy and utilities, telecommunications, retail, healthcare, financial services, entertainment and manufacturing. The Company operates in three segments: International, North America and IT Outsourcing. Its offerings are focused around a set of core competencies which include Application Development and Management (ADM), Enterprise Resource Planning (ERP), Customer Relationship Management, Business Intelligence and Data Warehousing, Managed Services, Testing and Quality Assurance, Mobility Services and Digital Marketing. On March 9, 2012, the Company sold its Federal division to CRGT, Inc.
International
The Company�� CIBER International division delivers a mix of ERP and custom ADM solutions. CIBER International offers a range of services covering the IT solution lifecycle to both commercial enterprises and public sector organizations. Key geographies for its International division include the Netherlands, the United Kingdom, Germany and the Scandinavian region consisting of Norway, Sweden and Denmark. The International division's enterprise solutions focus primarily on providing services related to ERP and Customer Relationship Management (CRM) software products, as well as managed services. It also provides SAP Industry Solutions, such as retail, automotive and chemicals, and it is a value-added reseller of SAP software in some international geographies. Th Company works with Microsoft to deliver ERP and CRM solutions in selected international geographies.
North America
The Company�� North America division was formed during the year ended December, 31, 2011, through the combination of its former Custom Solutions division and substantially all of its former U.S. ERP division. Its North America division is organized by and operates in a matrix! of geographies and practices. Its North America division provides ADM services, IT Strategy and Architecture, Business Intelligence/Data Warehousing, Collaborative Solutions, CRM and Supply Chain. The division also offers consulting services to support multi-package ERP solutions from vendors, including Oracle (including E-Business Suite, PeopleSoft and JD Edwards), SAP and Lawson, as well as several education management products. It is focused on industry solutions for vertical markets, such as telecommunications, healthcare, manufacturing, financial services, technology, state and local governments, higher education and entertainment.
The Company designs and develops custom-tailored offerings to suit its client's business needs. Its custom solutions provide a range of application portfolio management support, including analysis, design, development, testing, implementation, outsourcing and maintenance of business applications. Its service-oriented architectures, including J2EE and .NET, as well as traditional client/server and mainframe development. The Company also offers portal development, wireless and mobility applications and content delivery. The North America division is an Oracle Platinum Partner, which is a partnership in the Oracle Partner Network Specialized Program and a strategic partner to Oracle in several key industries, such as the public sector, higher education and food and beverage. Its Oracle, PeopleSoft and JD Edwards solutions involve building, integrating and supporting mission critical systems for real-time enterprises.
The Company�� North America division also is an SAP-certified global provider of application management services. The division's SAP solutions support their customers throughout the life cycle and include implementations and upgrades, extensions, integrations and customizations. The North America division has organized its SAP Practice to serve multiple vertical markets. In its SAP Commercial Practice, the North America division foc! uses on c! ustomers in retail, apparel and footwear, mining, metals, manufacturing, financial services and aerospace and defense industries. In its SAP Public Sector Practice, the North America division focuses on delivering solutions to state and local governments.
The North America division is a Certified Lawson Consulting Partner, providing business transformation projects in Lawson's target vertical markets through business process, change management and functional and technical services around Lawson technology. These target markets are healthcare, public sector, food and beverage and general manufacturing, for which it offers budgeting, financial processing and analysis, human capital management, sales order processing and manufacturing systems solutions.
IT Outsourcing
The Company�� IT Outsourcing division is a global business with domestic headquarters in Edison, New Jersey, and international presence throughout Europe. The division offers outsourced enterprise infrastructure management solutions, including managed hosted infrastructure, end user service desk and desktop services, remote infrastructure management (RIM) and application operations support. The IT Outsourcing division's data centers, service desk centers and global operations are located in the United States, United Kingdom, Poland, India and Spain. The division's Technology Solutions Group Practice focuses on providing customers with the infrastructure products and architecture. Offerings include enterprise servers, storage, middleware, integration services, assessments and related products required to support critical business applications.
The Company competes with Accenture plc, Cognizant Technology Solutions Corp, Infosys Technologies Limited, Perficient, Inc., Sapient Corp and The Hackett Group, Inc.
Advisors' Opinion:- [By Seth Jayson]
Ciber (NYSE: CBR ) is expected to report Q2 earnings on July 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Ciber's revenues will drop -4.8% and EPS will grow from $0.00 per share the prior year.
No comments:
Post a Comment